Primary Central Nervous System Vasculitis
NEJM 391:1028-1037, Salvarani,C.,et al, 2024
Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation
JAMA Neurol 73:197-202, Auriel, E.,et al, 2016
Clinicopathologic Conference, Susacs Syndrome (retinocochleocerebral vasculopathy)
NEJM 365:549-559, Case 24-2011, 2011
Primary Angiitis of the Central Nervous System
Arch Neurol 66:704-709, Birnbaum,J. &Hellmann,D.B., 2009
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
The Writing on the Wall
Lancet 372:344, Wilder-Smith,E.P. &Ng,E.S., 2008
Update on Susacs Syndrome
Curr Opin Neurol 18:311-314, Gross,M. &Eliashar,R., 2005
Neurologic Manifestations in Primary Sjogren Syndrome: A Study of 82 Patients
Medicine 83:280-291, Delalande,S.,et al, 2004
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Intermittent Cyclophosphamide Pulse Therapy in Progressive MS:NE Coop MS Trtm Grp
Neurol 43:910-918, Weiner,H.L.,et al, 1993
The Canadian Coop Trial of Cyclophosphamide and Plasma Exchange in Progr MS
The Canadian Coop MS Study Group, Lancet 337:441-4461991., , 1991
Intense Immunosuppression in Chronic Progressive Multiple Sclerosis:The Kaiser Study
JNNP 54:1055-1060, Likosky,W.H.,et al, 1991
Cyclophosphamide"Pulses"in Chronic Progressive Multiple Sclerosis, A Preliminary Clinical Trial
Arch Neurol 44:828-832, Myers,L.W.,et al, 1987
Cyclophosphamide in Chronic Progressive Multiple Sclerosis, Maintenance vs Nonmaintenance Therapy
Arch Neurol 44:823-827, Goodkin,D.E.,et al, 1987